Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a Study of HT-6184 in Subjects With IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndrome (MDS) and Symptomatic Anemia

Next Previous
Trial Profile

A Phase 2a Study of HT-6184 in Subjects With IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndrome (MDS) and Symptomatic Anemia

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ofirnoflast (Primary) ; Darbepoetin alfa; Epoetin alfa
  • Indications Myelodysplastic syndromes
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Halia Therapeutics

Most Recent Events

  • 10 Nov 2025 According to a Halia Therapeutics media release, the data from the trial will be presented at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition.
  • 04 Jun 2025 According to a Halia Therapeutics media release, an interim analysis was conducted following Stage 1, and topline results from the complete study are expected later this year.
  • 04 Jun 2025 According to a Halia Therapeutics media release, this two-stage study enrolled 18 evaluable patients in Stage 1 and has now completed enrollment of an additional 15 participants in Stage 2.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top